1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study

Introduction and Objective: Real-world data on the effectiveness and safety of second-generation basal insulin (BI) in insulin-naïve Chinese people with T2D uncontrolled with GLP-1 RAs are limited. Methods: IMPROVE G was a retrospective, single-arm, cohort study using data from the Tianjin regional electronic medical records database in northern China. Adult people with T2D uncontrolled with a GLP-1 RA (HbA1c 7-18%) who initiated Gla-300 between Jan 2021 and Dec 2024 were assessed (n=240), including people who added Gla-300 to GLP-1 RA (add-on BI) and those who switched to Gla-300. Mean changes from baseline in HbA1c, FPG, body weight, insulin dose, target achievement and hypoglycemia rates at 6 and 12 months were assessed. Subgroup analyses were conducted based on treatment regimen. Results: HbA1c and FPG significantly decreased by 0.98% and 2.05 mmol/L, respectively, at 6 months (both p<0.001). At 6 months, 35.4% of people achieved HbA1c <7%. Compared with baseline, no significant change in body weight was observed and there were significantly fewer hypoglycemia events. Gla-300 showed significant glycemic improvements across both subgroups at 6 months, with this effect maintained at 12 months. Conclusion: Gla-300 improved glycemic control with no body weight gain or no increase in hypoglycemia risk in Chinese people with insulin-naïve T2D uncontrolled with GLP-1 RAs in a real-world setting. Disclosure L. Duan: None. Y. Gong: None. G. Liu: None. H. Zhao: None. Z. Meng: None. J. Tong: None. S. Jiang: None. J. Cao: None. C. Xu: None. W. Liu: Employee; Current; Sanofi. Q. Du: Employee; Current; Sanofi China. L. Kang: Employee; Current; Sanofi China. M. Zhang: Employee; Current; Sanofi China. Funding This study was funded by Sanofi. Professional medical writing support was provided by Simone Tait, CMPP, of Springer Health+, and was funded by Sanofi.